Changes in lung function of HIV-infected patients: a 4.5-year follow-up study

Clin Physiol Funct Imaging. 2012 Jul;32(4):288-95. doi: 10.1111/j.1475-097X.2012.01124.x. Epub 2012 Mar 11.

Abstract

Objective: To investigate the development of lung function in HIV-infected patients.

Methods: In a prospective cohort study, 88 HIV-infected patients had a lung function test performed and 63 patients (72%) had their LFT repeated with a median follow-up period of 4.4 years. Forty-eight per cent were smokers, and at the re-examination, 97% were on combination antiretroviral therapy.

Results: Carbon monoxide diffusion capacity was reduced and decreased over time in both smokers and non-smokers. Alveolar volume decreased and forced vital capacity increased similarly in both smokers and non-smokers. No changes were observed in forced expiratory volume or peak flow, but smokers had reduced values compared with those of the non-smokers at both examinations. FEV1/FVC was reduced especially in smokers and declined in both smokers and non-smokers.

Conclusions: Carbon monoxide diffusion capacity is reduced in HIV-infected patients and seems to decline over time. Additionally, signs of obstructive lung disease are present in HIV-infected patients and seem to increase over time, although only modestly.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • Denmark
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Forced Expiratory Volume
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / physiopathology
  • HIV Infections / virology
  • Humans
  • Lung / physiopathology*
  • Lung / virology
  • Lung Volume Measurements
  • Male
  • Middle Aged
  • Outpatient Clinics, Hospital
  • Prognosis
  • Prospective Studies
  • Pulmonary Diffusing Capacity
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / etiology*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Pulmonary Disease, Chronic Obstructive / virology
  • Smoking / adverse effects
  • Time Factors
  • Vital Capacity

Substances

  • Anti-Retroviral Agents